ICCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Icecure Medical Ltd (ICCM) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has promising technology and market potential, its financial performance and lack of clear trading signals suggest that waiting for further developments or a stronger entry point would be prudent.
The MACD is positive and expanding, indicating a bullish momentum. RSI is neutral at 69.828, and moving averages are converging, suggesting indecision. The current pre-market price of 0.66345 is near the R1 resistance level of 0.654, with the next resistance at 0.679. There is no strong technical signal for a breakout or significant upward movement.
The ProSense® cryoablation technology has shown strong efficacy and safety in independent studies, with FDA clearance for low-risk breast cancer treatment. The technology has significant market potential, addressing 63,000 cases annually in the U.S.
The company's financials show declining net income, EPS, and gross margin in Q3 2025, raising concerns about profitability and operational efficiency. Additionally, there are no significant trading trends from hedge funds or insiders, and no recent congress trading data.
In Q3 2025, revenue increased by 28.40% YoY to $850,000, but net income dropped by 6.99% YoY to -$3,859,000. EPS fell by 25.00% YoY to -0.06, and gross margin decreased by 8.20% YoY to 32.59%. While revenue growth is positive, the declining profitability metrics are concerning.
No analyst rating or price target changes are available for ICCM at this time.
